当前位置: 首页 >> 检索结果
4981. Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction.
作者: Gijs van Woerden.;Dirk J van Veldhuisen.;Olivier C Manintveld.;Vanessa P M van Empel.;Tineke P Willems.;Rudolf A de Boer.;Michiel Rienstra.;B Daan Westenbrink.;Thomas M Gorter.
来源: Circ Heart Fail. 2022年15卷3期e009238页
Epicardial adipose tissue (EAT) accumulation is thought to play a role in the pathophysiology of heart failure (HF) with mid-range and preserved ejection fraction, but its effect on outcome is unknown. We evaluated the prognostic value of EAT volume measured with cardiac magnetic resonance in patients with HF with mid-range ejection fraction and HF with preserved ejection fraction.
4983. Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results From the CABANA Trial.
作者: Tristram D Bahnson.;Anna Giczewska.;Daniel B Mark.;Andrea M Russo.;Kristi H Monahan.;Hussein R Al-Khalidi.;Adam P Silverstein.;Jeanne E Poole.;Kerry L Lee.;Douglas L Packer.; .
来源: Circulation. 2022年145卷11期796-804页
Observational data suggest that catheter ablation may be safe and effective to treat younger and older patients with atrial fibrillation. No large, randomized trial has examined this issue. This report describes outcomes according to age at entry in the CABANA trial (Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation).
4984. Percutaneous Coronary Intervention Following Diagnostic Angiography by Noninterventional Versus Interventional Cardiologists: Insights From the CathPCI Registry.
作者: Fabio V Lima.;Pratik Manandhar.;Daniel Wojdyla.;Tracy Wang.;Herbert D Aronow.;Vishnu Kadiyala.;E Hope Weissler.;Nidhi Madan.;Ian C Gilchrist.;Cindy Grines.;J Dawn Abbott.
来源: Circ Cardiovasc Interv. 2022年15卷1期e011086页
There are limited contemporary, national data describing diagnostic cardiac catheterization with subsequent percutaneous coronary intervention (ad hoc percutaneous coronary intervention [PCI]) performed by an invasive-diagnostic and interventional (Dx/IC) operator team versus solo interventional operator (solo-IC). Using the CathPCI Registry, this study aimed at analyzing trends and outcomes in ad hoc PCI among Dx/IC versus solo-IC operators.
4985. Arrhythmia Variant Associations and Reclassifications in the eMERGE-III Sequencing Study.
作者: Andrew M Glazer.;Giovanni Davogustto.;Christian M Shaffer.;Carlos G Vanoye.;Reshma R Desai.;Eric H Farber-Eger.;Ozan Dikilitas.;Ning Shang.;Jennifer A Pacheco.;Tao Yang.;Ayesha Muhammad.;Jonathan D Mosley.;Sara L Van Driest.;Quinn S Wells.;Lauren Lee Shaffer.;Olivia R Kalash.;Yuko Wada.;Harris T Bland.;Zachary T Yoneda.;Devyn W Mitchell.;Brett M Kroncke.;Iftikhar J Kullo.;Gail P Jarvik.;Adam S Gordon.;Eric B Larson.;Teri A Manolio.;Tooraj Mirshahi.;Jonathan Z Luo.;Daniel Schaid.;Bahram Namjou.;Tarek Alsaied.;Rajbir Singh.;Ashutosh Singhal.;Cong Liu.;Chunhua Weng.;George Hripcsak.;James D Ralston.;Elizabeth M McNally.;Wendy K Chung.;David S Carrell.;Kathleen A Leppig.;Hakon Hakonarson.;Patrick Sleiman.;Sunghwan Sohn.;Joseph Glessner.; .;Joshua Denny.;Wei-Qi Wei.;Alfred L George.;M Benjamin Shoemaker.;Dan M Roden.
来源: Circulation. 2022年145卷12期877-891页
Sequencing Mendelian arrhythmia genes in individuals without an indication for arrhythmia genetic testing can identify carriers of pathogenic or likely pathogenic (P/LP) variants. However, the extent to which these variants are associated with clinically meaningful phenotypes before or after return of variant results is unclear. In addition, the majority of discovered variants are currently classified as variants of uncertain significance, limiting clinical actionability.
4986. Impact of Interdisciplinary System-Wide Limb Salvage Advisory Council on Lower Extremity Major Amputation.
作者: Mehdi H Shishehbor.;Tarek A Hammad.;Tonia J Rhone.;Ahmad Younes.;Norman Kumins.;Abdullah Abdullah.;Jun Li.;Karem Harth.;Teresa L Carman.;Heather L Gornik.;Peter J Pronovost.;Vikram S Kashyap.
来源: Circ Cardiovasc Interv. 2022年15卷1期e011306页 4987. Long-Term Outcomes After Melody Transcatheter Pulmonary Valve Replacement in the US Investigational Device Exemption Trial.
作者: Thomas K Jones.;Doff B McElhinney.;Julie A Vincent.;William E Hellenbrand.;John P Cheatham.;Darren P Berman.;Evan M Zahn.;Danyal M Khan.;John F Rhodes.;Shicheng Weng.;Lisa J Bergersen.
来源: Circ Cardiovasc Interv. 2022年15卷1期e010852页
The Melody valve was developed to extend the useful life of previously implanted right ventricular outflow tract (RVOT) conduits or bioprosthetic pulmonary valves, while preserving RV function and reducing the lifetime burden of surgery for patients with complex congenital heart disease.
4990. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
作者: Perry Elliott.;Brian M Drachman.;Stephen S Gottlieb.;James E Hoffman.;Scott L Hummel.;Daniel J Lenihan.;Ben Ebede.;Balarama Gundapaneni.;Benjamin Li.;Marla B Sultan.;Sanjiv J Shah.
来源: Circ Heart Fail. 2022年15卷1期e008193页
Tafamidis is approved in many countries for the treatment of transthyretin amyloid cardiomyopathy. This study reports data on the long-term efficacy of tafamidis from an ongoing long-term extension (LTE) to the pivotal ATTR-ACT (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
4993. Inflammatory Glycoprotein 130 Signaling Links Changes in Microtubules and Junctophilin-2 to Altered Mitochondrial Metabolism and Right Ventricular Contractility.
作者: Sasha Z Prisco.;Lynn M Hartweck.;Lauren Rose.;Patricia D A Lima.;Thenappan Thenappan.;Stephen L Archer.;Kurt W Prins.
来源: Circ Heart Fail. 2022年15卷1期e008574页
Right ventricular dysfunction (RVD) is the leading cause of death in pulmonary arterial hypertension (PAH), but no RV-specific therapy exists. We showed microtubule-mediated junctophilin-2 dysregulation (MT-JPH2 pathway) causes t-tubule disruption and RVD in rodent PAH, but the druggable regulators of this critical pathway are unknown. GP130 (glycoprotein 130) activation induces cardiomyocyte microtubule remodeling in vitro; however, the effects of GP130 signaling on the MT-JPH2 pathway and RVD resulting from PAH are undefined.
4994. PRDM16 Is a Compact Myocardium-Enriched Transcription Factor Required to Maintain Compact Myocardial Cardiomyocyte Identity in Left Ventricle.
作者: Tongbin Wu.;Zhengyu Liang.;Zengming Zhang.;Canzhao Liu.;Lunfeng Zhang.;Yusu Gu.;Kirk L Peterson.;Sylvia M Evans.;Xiang-Dong Fu.;Ju Chen.
来源: Circulation. 2022年145卷8期586-602页
Left ventricular noncompaction cardiomyopathy (LVNC) was discovered half a century ago as a cardiomyopathy with excessive trabeculation and a thin ventricular wall. In the decades since, numerous studies have demonstrated that LVNC primarily has an effect on left ventricles (LVs) and is often associated with LV dilation and dysfunction. However, in part because of the lack of suitable mouse models that faithfully mirror the selective LV vulnerability in patients, mechanisms underlying the susceptibility of LVs to dilation and dysfunction in LVNC remain unknown. Genetic studies have revealed that deletions and mutations in PRDM16 (PR domain-containing 16) cause LVNC, but previous conditional Prdm16 knockout mouse models do not mirror the LVNC phenotype in patients, and the underlying molecular mechanisms by which PRDM16 deficiency causes LVNC are still unclear.
4995. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.
作者: Matthew A Cavender.;Robert A Harrington.;Gregg W Stone.;Ph Gabriel Steg.;C Michael Gibson.;Christian W Hamm.;Matthew J Price.;Renato D Lopes.;Sergio Leonardi.;Efthymios N Deliargyris.;Jayne Prats.;Kenneth W Mahaffey.;Harvey D White.;Deepak L Bhatt.; .
来源: Circ Cardiovasc Interv. 2022年15卷1期e010390页
Thrombotic events are reduced with cangrelor, an intravenous P2Y12 inhibitor. We sought to characterize the timing, number, and type of early events (within 2 hours of randomization) in CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention).
4996. Racial Disparities in Invasive Management for Patients With Acute Myocardial Infarction With Chronic Kidney Disease.
作者: Jennifer A Rymer.;Shuang Li.;Patrick H Pun.;Laine Thomas.;Tracy Y Wang.
来源: Circ Cardiovasc Interv. 2022年15卷1期e011171页
Due to increased risks of contrast nephropathy, chronic kidney disease (CKD) can deter consideration of invasive management for patients with myocardial infarction (MI). Black patients have a higher prevalence of CKD. Whether racial disparities exist in the use of invasive MI management for patients with CKD presenting with MI is unknown.
4997. AtheroSpectrum Reveals Novel Macrophage Foam Cell Gene Signatures Associated With Atherosclerotic Cardiovascular Disease Risk.
作者: Chuan Li.;Lili Qu.;Alyssa J Matz.;Patrick A Murphy.;Yongmei Liu.;Ani W Manichaikul.;Derek Aguiar.;Stephen S Rich.;David M Herrington.;David Vu.;W Craig Johnson.;Jerome I Rotter.;Wendy S Post.;Anthony T Vella.;Annabelle Rodriguez-Oquendo.;Beiyan Zhou.
来源: Circulation. 2022年145卷3期206-218页
Whereas several interventions can effectively lower lipid levels in people at risk for atherosclerotic cardiovascular disease (ASCVD), cardiovascular event risks remain, suggesting an unmet medical need to identify factors contributing to cardiovascular event risk. Monocytes and macrophages play central roles in atherosclerosis, but studies have yet to provide a detailed view of macrophage populations involved in increased ASCVD risk.
4998. DREAM-ICD-II Study.
作者: Christian Steinberg.;Nicolas Dognin.;Amit Sodhi.;Catherine Champagne.;John A Staples.;Jean Champagne.;Zachary W Laksman.;Jean-François Sarrazin.;Matthew T Bennett.;Benoit Plourde.;Marc W Deyell.;Jason G Andrade.;Karine Roy.;John A Yeung-Lai-Wah.;Nathaniel M Hawkins.;Blandine Mondésert.;Louis Blier.;Isabelle Nault.;Gilles O'Hara.;Andrew D Krahn.;François Philippon.;Santabhanu Chakrabarti.
来源: Circulation. 2022年145卷10期742-753页
Regulatory authorities of most industrialized countries recommend 6 months of private driving restriction after implantation of a secondary prevention implantable cardioverter-defibrillator (ICD). These driving restrictions result in significant inconvenience and social implications. This study aimed to assess the incidence rate of appropriate device therapies in contemporary recipients of a secondary prevention ICD.
4999. Factors Associated With Racial and Ethnic Diversity Among Heart Failure Trial Participants: A Systematic Bibliometric Review.
作者: Sunny Wei.;NhatChinh Le.;Jie Wei Zhu.;Khadijah Breathett.;Stephen J Greene.;Mamas A Mamas.;Faiez Zannad.;Harriette G C Van Spall.
来源: Circ Heart Fail. 2022年15卷3期e008685页
Heart failure has a disproportionate burden on patients who are Black, Indigenous, and people of color (BIPOC), but not much is known about representation of these groups in randomized controlled trials (RCTs). We explored temporal trends in and RCT factors associated with the reporting of race and ethnicity data and the enrollment of BIPOC in heart failure RCTs.
5000. Detection of Left Atrial Myopathy Using Artificial Intelligence-Enabled Electrocardiography.
作者: Frederik H Verbrugge.;Yogesh N V Reddy.;Zachi I Attia.;Paul A Friedman.;Peter A Noseworthy.;Francisco Lopez-Jimenez.;Suraj Kapa.;Barry A Borlaug.
来源: Circ Heart Fail. 2022年15卷1期e008176页
Left atrial (LA) myopathy is common in patients with heart failure and preserved ejection fraction and leads to the development of atrial fibrillation (AF). We investigated whether the likelihood of LA remodeling, LA dysfunction, altered hemodynamics, and risk for incident AF could be identified from a single 12-lead ECG using a novel artificial intelligence (AI)-enabled ECG analysis.
|